First Tracks Biotherapeutics (NASDAQ:TRAX) Now Covered by Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. started coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a report released on Thursday. The brokerage set an “overweight” rating and a $31.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 64.28% from the company’s previous close.

A number of other research analysts also recently commented on the stock. Barclays began coverage on shares of First Tracks Biotherapeutics in a research report on Wednesday. They set an “overweight” rating and a $40.00 price objective on the stock. UBS Group began coverage on shares of First Tracks Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, First Tracks Biotherapeutics presently has a consensus rating of “Buy” and an average target price of $38.67.

First Tracks Biotherapeutics Stock Up 11.0%

Shares of TRAX opened at $18.87 on Thursday. First Tracks Biotherapeutics has a 52 week low of $14.79 and a 52 week high of $26.80.